<DOC>
	<DOC>NCT00260039</DOC>
	<brief_summary>This dose-ranging study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate that the vaccine is well-tolerated in women (2) To evaluate immune responses in women who are between 16 and 23 years of age at enrollment.</brief_summary>
	<brief_title>Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Lifetime history of 04 sexual partners History of abnormal PAP test or abnormal cervical biopsy result; history of external genital/vaginal warts; history of positive HPV test</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>